Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04236427
Other study ID # ANP study
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date October 15, 2019
Est. completion date June 30, 2023

Study information

Verified date January 2021
Source Chinese University of Hong Kong
Contact Alexander Yuk-lun LAU, Post-doc
Phone 3505 3476
Email alexlau@cuhk.edu.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of using Chinese Medicine Angong Niuhuang Wan in stroke patients, the modified Rankin Scale (mRS) score will be used as primary outcome, the National Institutes of Health Stroke Scale (NIHSS) score, The Modified Barthel Index (MBI) score and the Montreal Cognitive Assessment (MoCA) scores will be used as secondary outcome measures.


Description:

This study is a randomized, double-blind, placebo-controlled trial which is used to further determine the effectiveness of Angong Niuhuang Wan in treating stroke patients on top of the standard conventional treatment, also to evaluate the improvement level on quality of life of post-stroke after using Angong Niuhuang Wan. The effect of Angong Niuhuang Wan on liver and kidney function will be focused and using NMR techniques to analysis metabolomics to further study the safety and effectiveness of Angong Niuhuang Wan on the prevention and treatment of stroke. It is a 24-week trial, Double-blind treatment for 1 week, follow up visit for 23 weeks. All participant will have study blood taking for renal and liver function test and questionnaires assessment during study visits. Informed consent will be obtained before study enrollment.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 30, 2023
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: 1. Chinese adults aged 40 or above; 2. diagnosed as a stroke by a neurologist, with imaging of CT or MRI support; 3. Neurologist confirms the symptoms of stroke occur within 28 days and are clinically stable. In the past 48 hours, the condition of the nervous system has not deteriorated significantly; 4. TCM diagnosis is a stroke and belongs to a heat syndrome; 5. There is a movement defect caused by stroke; 6. The severity of stroke was scored 5-25 by the National Institutes of Health Brain Stroke Scale (NIHSS); 7. Informed consent will be given by participant or its representatives Exclusion Criteria: 1. The movement defects are not associated with stroke. Before commencement of study treatment, patient has physical activity dysfunction caused by lameness , osteoarthritis, rheumatoid arthritis, gouty arthritis, etc. that may affect neurological function examination; 2. Subjects are unlikely to come back for follow-up visits during the 24-week study period; 3. The subject has a brain tumor on a computed tomography scan (CT); 4. The subject has thrombocytopenia (known platelet count <100,000 / mm3) or coagulopathy disease; 5. Taking warfarin or other anticoagulant; 6. Concomitant diseases such as severe hypertension or diabetes; 7. Comorbidities or complications associated with drug evaluation; 8. Pregnant or breast-feeding female. 9. The alanine aminotransferase (ALT) value is 1.5 times higher than the normal maximum value in liver function test and the estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m2 in the renal function test. 10. Present the sign of pure yin syndrome or yin / yang defecation in TCM diagnosis; 11. Subject has G6PD 12. Known swallowing problem 13. Dependent in all daily life activities

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Angong Niuhuang Wan
Angong Niuhuang Wan 3g
Angong Niuhuang Wan Placebo
Angong Niuhuang Wan Placebo 3g

Locations

Country Name City State
Hong Kong The Chinese University of Hong Kong Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Score of neurological deficit and adverse events compare the therapeutic effects, the score of neurological deficit and adverse events between the two groups by using questionnaire of mRS, higher scores mean a worse outcome 24 weeks
Secondary Mortality and recurrence rates of stroke Compare the mortality and recurrence rates of stroke between two groups also the abilities of daily ability using questionnaires of NIHSS (higher scores mean a worse outcome), mBI and MOCA-HK (higher scores mean a better outcome) 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06115213 - The North Kynouria Project N/A
Recruiting NCT06192953 - Early Functional Proprioceptive Stimulation Post-stroke N/A
Completed NCT04845269 - Post-Stroke Osteopathy
Completed NCT05771805 - Additional Effects of Vagus Nerve Stimulation on Motor Functions of Upper-limb in Stroke N/A
Completed NCT05945784 - Exploring Accessible Beauty for Individuals With Upper Extremity Deficits
Not yet recruiting NCT05658315 - Investigating the Efficacy of ApplTree on Prospective Memory in Stroke N/A
Recruiting NCT06291480 - Music Therapy After Stroke (Subacute Phase) N/A
Recruiting NCT05719883 - Evaluating the Safety and Efficacy of the Maurora® DES in ICAS N/A
Completed NCT04636658 - Effects of Resistive Diaphragmatic Training on Chronic Stroke N/A
Withdrawn NCT04580238 - Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache Phase 1
Recruiting NCT05878457 - Accelerated rTMS for Post-Stroke Apathy Phase 1
Recruiting NCT05885295 - The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
Not yet recruiting NCT05319418 - Effectiveness of BP Remote Monitoring With Virtual Physician Management in Hypertensive Patients. N/A
Withdrawn NCT05780060 - Multiple Organized Systems for Engaging Stroke (MOSES) N/A